title: Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy.
abstract: OBJECTIVE
  Transplantation of mesenchymal stromal cells (MSC) derived from bone marrow (BM) or adipose tissue is expected to become a cell therapy for stroke. The present study compared the therapeutic potential of adipose-derived stem cells (ASC) with that of BM-derived stem cells (BMSC) in a murine stroke model.
  
  
  METHODS
  ASC and BMSC were isolated from age-matched C57BL/6J mice. These MSC were analyzed for growth kinetics and their capacity to secrete trophic factors and differentiate toward neural and vascular cell lineages in vitro. For in vivo study, ASC or BMSC were administrated intravenously into recipient mice (1 × 10(5) cells/mouse) soon after reperfusion following a 90-min middle cerebral artery occlusion. Neurologic deficits, the degree of infarction, expression of factors in the brain, and the fate of the injected cells were observed.
  
  
  RESULTS
  ASC showed higher proliferative activity with greater production of vascular endothelial cell growth factor (VEGF) and hepatocyte growth factor (HGF) than BMSC. Furthermore, in vitro conditions allowed ASC to differentiate into neural, glial and vascular endothelial cells. ASC administration showed remarkable attenuation of ischemic damage, although the ASC were not yet fully incorporated into the infarct area. Nonetheless, the expression of HGF and angiopoietin-1 in ischemic brain tissue was significantly increased in ASC-treated mice compared with the BMSC group.
  
  
  CONCLUSIONS
  Compared with BMSC, ASC have great advantages for cell preparation because of easier and safer access to adipose tissue. Taken together, our findings suggest that ASC would be a more preferable source for cell therapy for brain ischemia than BMSC.
authors.affiliation: Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, Japan. ikegame-nsu@umin.ac.jp
authors.forename: Yuka
authors.initials: Y
authors.lastname: Ikegame
authors.forename: Kentaro
authors.initials: K
authors.lastname: Yamashita
authors.forename: Shin-Ichiro
authors.initials: S
authors.lastname: Hayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Mizuno
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tawada
authors.forename: Fukka
authors.initials: F
authors.lastname: You
authors.forename: Kiyofumi
authors.initials: K
authors.lastname: Yamada
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Egashira
authors.forename: Shigeru
authors.initials: S
authors.lastname: Nakashima
authors.forename: Shin-Ichi
authors.initials: S
authors.lastname: Yoshimura
authors.forename: Toru
authors.initials: T
authors.lastname: Iwama
mesh_terms: D000273:Adipose Tissue / Q000166:cytology*; D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology*; D002545:Brain Ischemia / Q000378:metabolism / Q000628:therapy; D064987:Cell- and Tissue-Based Therapy; D017228:Hepatocyte Growth Factor / Q000378:metabolism; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology*; D051379:Mice; D008810:Mice, Inbred C57BL; D020521:Stroke / Q000378:metabolism / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D042461:Vascular Endothelial Growth Factor A; D017228:Hepatocyte Growth Factor